Analgesia y manejo del
Analgesia y manejo del Dolor 1:2, Agosto de 2024 14. Nasrallah R, Hébert RL. Prostacyclin signaling in the kidney: Implications for health and disease. Am J Physiol (Renal Physiol) 2005; 289: F235-46. doi: 10.1152/ajprenal.00454.2004. 15. Nasrallah R, Hassouneh R, Hébert RL. PGE2, Kidney disease, and cardiovascular risk: Beyond hypertension and diabetes. J Am Soc Nephrol 2016; 27: 666-76. doi: 10.1681/ASN.2015050528. 16. Harris RC, Breyer MD. Update on cyclooxygenase-2 inhibitors. Clin J Am Soc Nephrol 2006; 1: 236- 45. doi: 10.2215/CJN.00890805. 17. Patrono C, Baigent C. Nonsteroidal anti-inflammatory drugs and the heart. Circulation 2014; 129: 907-16. doi: 10.1161/CIRCULATIONA- HA.113.004480. 18. Langenbach R, Loftin CD, Lee C, Tiano H. Cyclooxygenase-deficient mice. A summary of their characteristics and susceptibilities to inflammation and carcinogenesis. Ann N Y Acad Sci 1999; 889: 52-61. doi: 10.1111/j.1749-6632.1999.tb08723.x. 19. Caiazzo E, Ialenti A, Cicala C. The relatively selective cyclooxygenase-2 inhibitor nimesulide: What’s going on? Eur J Pharmacol 2019; 848: 105-11. doi: 10.1016/j.ejphar.2019.01.044. 20. Davies NM, Good RL, Roupe KA, Yáñez JA. Ciclooxygenase-3: Axiom, dogma, anomaly, enigma or splice error? - not as easy as 1, 2, 3. J Pharm Pharmaceut Sci 2004; 7: 217-26. Erratum in: J Pharm Pharm Sci 2006; 9: following 433. 21. Ortiz MI, Torres-López JE, Castañeda-Hernández G, et al. Pharmacological evidence for the activation of K(+) channels by diclofenac. Eur J Pharmacol 2002; 438: 85-91. doi: 10.1016/s0014-2999(02)01288- 8. 22. dos Santos GG, Dias EV, Teixeira JM, Athie MC, Bonet IJ, Tambeli CH, Parada CA. The analgesic effect of dipyrone in peripheral tissue involves two different mechanisms: Neuronal K(ATP) channel opening and CB(1) receptor activation. Eur J Pharmacol. 2014; 741: 124-31. doi: 10.1016/j.ejphar.2014.07.019. 23. Tegeder I, Pfeilschifter J, Gleisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 2001; 15: 2057-72. doi: 10.1096/ fj.01-0390rev. 24. Pacher P, Batkai S, Kunos G. The endocanabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006; 58: 389-462. doi: 10.1124/ pr.58.3.2. 25. Graham GG, Scott KF. Mechanisms of action of paracetamol. Am J Ther 2005; 12: 46-55. doi: 10.1097/00045391-200501000-00008. 26. Smyth EM, Burke A, FitzGerald GA. Lipid-derived Autacoids: Eicosanoids and Platelet-activated Factor. In Brunton LL, Lazo JS, Parker KL, eds. Goodman & Gilman´s The Pharmacological Basis of Therapeutics 11th ed. New York: McGraw Hill 2006; pp 653-70. 27. Minuz P, Fava C, Lechi A. Lipid peroxidation, isoprostanes and vascular damage. Pharmacol Rep 2006; 58 (suppl): 57-68. 28. Power I. Aspirin-induced asthma. Br J Anaesth 1993; 71: 619-21. doi: 10.1093/bja/71.5.619. 29. Wallace JL, Granger DN. Pathogenesis of NSAID gastropathy: Are neutrophils the culprits? Trends Pharmacol Sci 1992; 13: 129-30. doi: 10.1016/0165- 6147(92)90046-9. 30. Christie MJ, Vaughan CW, Ingram SL. Opioids, NSAIDs and 5-lipoxygenase inhibitors act synergistically in brain via arachidonic acid metabolism. Inflamm Res 1999; 48:1-4. doi: 10.1007/s000110050367. 31. Yaksh TL. Spinal systems and pain processing: Development of novel analgesic drugs with mechanistically defined models. Trends Pharmacol Sci 1999; 20: 329-37. doi: 10.1016/s0165-6147(99)01370-x. 32. Siiskonen H, Harvima I. Mast cells and sensory nerves contribute to neurogenic inflammation and pruritus in chronic skin inflammation. Front Cell Neurosci 2019; 13: 422. doi: 10.3389/fncel.2019.00422. 33. Lugrin J, Rosenblatt-Velin N, Parapanov R, Liaudet L. The role of oxidative stress during inflammatory processes. Biol Chem 2014; 395: 203-30. doi: 10.1515/hsz-2013-0241. 34. Cook AD, Christensen AD, Tewari D, McMahon SB, Hamilton JA. Immune cytokines and their receptors in inflammatory pain. Trends Inmunol 2018; 39: 240-55. doi: 10.1016/j.it.2017.12.003. 35. Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-kB pathway in the treatment of inflammation and cancer. J Clin Invest 2001; 107: 135-42. doi: 10.1172/JCI11914. 36. Frantz B, O’Neill EA. The effect of sodium salicylate and aspirin on NF-kappa B. Science 1995; 270: 2017-9. doi: 10.1126/science.270.5244.2017. 37. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1997; 272: 3406-10. doi: 10.1074/ jbc.272.6.3406. 38. Puhl AC, Milton FA, Cvoro A, Sieglaff DH, Campos JC, Bernardes A, et al. Mechanisms of peroxisome proliferator activated receptor g regulation by non-steroidal anti-inflammatory drugs. Nucl Recept Signal 2015; 13: e004. doi: 10.1621/nrs.13004. 39. Mastbergen SC, Jansen NW, Bijlsma JW, Lafeber FP. Differential direct effects of cyclo-oxygenase-1/2 inhibition on proteoglycan turnover of human osteoarthritic cartilage: An in vitro study. Arthritis Res Ther 2006; 8: R2. doi: 10.1186/ar1846. 40. Manicourt DH, Bevilacqua M, Righini V, Famaey JP, Devogelaer JP. Comparative effect of nimesulide and ibuprofen on the urinary levels of collagen type II C-telopeptide degradation products and on serum levels of hyaluronan and matrix metalloproteinases-3 and -13 in patients with flare-up of osteoarthritis. Drug R D 2005; 6: 261-71. doi: 10.2165/00126839- 200506050-00002. 41. Kis B, Snipes JA, Busija DW. Acetaminophen and the cyclooxygenase-3 puzzle: Sorting out facts, fictions and uncertainties. J Pharmacol Exp Ther 2005; 315: 1-7. doi: 10.1124/jpet.105.085431. 42. Iannantuono R, Devoto FM. Capítulo 6 Farmacología Clínica. En: Zieher LM, Iannatuono RF, Serra HA, eds. Farmacología General y de la Neurotransmisión 3ra ed. Buenos Aires: Ursino 2003; pp 101-22. 43. Non-steroidal anti-inflammatory drugs (NSAIDs). In Aronson JK, Dukes MNG, eds. Meyler´s Side Effects of Drugs. The International Encyclopaedia of Adverse Drug Reactions and Interactions 15th ed. Amsterdam: Elsevier 2006; pp 2555-82. 44. Samer CF, Piguet V, Dayer P, Desmeules JA. Polymorphisme génétique et interactions médicamenteuses: leur importance dans le traitement de la douleur. Can J Anaesth 2005; 52: 806-21. doi: 10.1007/ BF03021775. 45. Laufer S. Osteoarthritis therapy-are there still unmet needs? Rheumatology 2004; 43 (suppl 1): i9-15. doi: 10.1093/rheumatology/keh103. 46. Goldstein JL, Eisen GM, Lewis B, Gralnek IM, Zlotnick S, Fort JG. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazol, and placebo. Clin Gastroenterol Hepatol 2005; 3: 133-41. 47. Talley JJ. Selective inhibitors of cyclooxygenase-2 (COX-2). Prog Med Chem 1999; 36: 201-34. doi: 10.1016/s0079-6468(08)70048-1. 48. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW Jr. Aspirin use and risk of fatal cancer. Cancer Res 1993; 53: 1322-7. 49. Fujimura T, Ohta T, Oyama K, Miyashita T, Miwa K. Cyclooxygenase-2 (COX-2) in carcinogenesis and selective COX-2 inhibitors for chemoprevention in gastrointestinal cancers. J Gastrointest Cancer 2007; 38: 78-82. doi: 10.1007/s12029-008-9035-x. 50. Harris RE, Beebe-Donk J, Alshafie GA. Cancer chemoprevention by cyclooxygenase 2 (COX-2) blockade: Results of case control studies. Subcell Biochem 2007; 42:193-212. doi: 10.1007/1-4020- 5688-5_9. 51. Cerchietti LC, Navigante AH, Peluffo GD, Diament MJ, Stillitani I, Klein SA, Cabalar ME. Effects of celecoxib, medroxyprogesterone, and dietary intervention on systemic syndromes in patients with advanced lung adenocarcinoma: A pilot study. J Pain Symptom Manage 2004; 27: 85-95. doi: 10.1016/j.jpainsymman.2003.05.010. 52. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520-8. 10.1056/ NEJM200011233432103. 53. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092- 102. doi: 10.1056/NEJMoa050493. Erratum in: N Engl J Med 2006; 355: 221. 54. Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: Therapeutic challenges and opportunities. J Clin Invest 2006; 116: 4-15. doi: 10.1172/JCI27291. 55. Kearny PM, Baigent C, Godwin J, Emberson H, Halls JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steriodal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006; 332:1302-5. doi: 10.1136/bmj.332.7553.1302. 56. Whelton A, Hamilton CW. Nonsteroidal anti-inflammatory drugs: effects on kidney function. J Clin Pharmacol 1991; 31: 588-98. doi: 10.1002/j.1552- 4604.1991.tb03743.x. 57. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: A systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006; 296: 1633-44. doi: 10.1001/jama.296.13.jrv60011. 58. Kerr DJ, Dunn JA, Langman MJ, Smith JL, Midgley RS, Stanley A, et al. Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer. N Engl J Med 2007; 357: 360-9. doi: 10.1056/ NEJMoa071841. 59. O´Connor N, Dargan PI, Jones AL. Hepatocellular damage from non-steroidal anti-inflammatory drugs. QJM 2003; 96: 787-91. doi: 10.1093/qjmed/ hcg138. 60. Tang W. The metabolism of diclofenac-enzymology and toxicology perspectives. Curr Drug Metab 2003; 4: 319-29. doi: 10.2174/1389200033489398. 61. Antiinflamatorios no esteroides y específicos. En Litter M. Farmacología Experimental y Clínica 7ma ed. Buenos Aires: Editorial El Ateneo 1986; pp 1303-36. 62. Heymann MA, Rudolph AM, Silverman NH. Closure of the ductus arteriosus in premature infants by inhibition of prostaglandin synthesis. N Engl J Med 1976; 295: 530-3. doi: 10.1056/ NEJM197609022951004. 63. McLaren AC. Prophylaxis with indomethacin for heterotopic bone. After open reduction of fractures of the acetabulum. J Bone Joint Surg Am 1990; 72: 245-7. 64. Mahony L, Carnero V, Brett C, Heymann MA, Clyman RI. Prophylactic indomethacin therapy for patient ductus arteriosus in very-low-birth-weight infants. N Engl J Med 1982; 306: 506-10. doi: 10.1056/ NEJM198203043060903. 65. Moise KJ Jr, Huhta JC, Sharif DS, Ou CN, Kirshon B, Wasserstrum N, Cano L. Indomethacin in the treatment of premature labor. Effects on the fetal ductus arteriosus. N Engl J Med 1988; 319: 327-31. doi: 10.1056/NEJM198808113190602. 66. Rodrigues AD. Impact of CYP2C9 genotype on pharmacokinetics: Are all cyclooxygenase inhibitors the same? Drug Metab Dispos 2005; 33: 1567-75. doi: 10.1124/dmd.105.006452. EDITORIAL SCIENS // 13
